<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85815">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02092350</url>
  </required_header>
  <id_info>
    <org_study_id>5172-052</org_study_id>
    <secondary_id>2013-003858-25</secondary_id>
    <nct_id>NCT02092350</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MK-5172 + MK-8742 in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052/C-SURFER)</brief_title>
  <official_title>A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of combination treatment with MK-5172 +
      MK-8742 for non-cirrhotic participants with chronic Genotype 1 (GT1) hepatitis C virus (HCV)
      infection and chronic kidney disease (CKD).  After a screening period, participants will
      receive random assignment to one of two study arms (immediate treatment or deferred
      treatment,) or assignment to open-label immediate treatment with intensive pharmacokinetic
      sampling.  The primary study hypothesis is that the proportion of participants achieving a
      sustained viral response 12 weeks after the end of all study treatment (SVR12) will be &gt;45%.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants achieving sustained viral response 12 weeks after the end of all treatment (SVR12)</measure>
    <time_frame>Up to 28 weeks, depending on arm assignment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events</measure>
    <time_frame>Up to 52 weeks, depending on arm assignment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study drug due to AEs</measure>
    <time_frame>Up to 28 weeks, depending on arm assignment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing SVR 4 weeks after the end of all treatment (SVR4)</measure>
    <time_frame>Up to 32 weeks, depending on arm assignment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing SVR 24 weeks after the end of all treatment (SVR24)</measure>
    <time_frame>Up to Week 52, depending on arm assignment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Immediate Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MK-5172 100 mg tablet, orally, once per day (QD) + MK-8742 50 mg tablet, orally, QD, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive placebo to MK-5172 and MK-8742 for 12 weeks, and after a 4-week break, MK-5172 100 mg tablet, orally, QD + MK-8742 50 mg tablet, orally, QD for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate Treatment/PK Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive MK-5172 100 mg tablet, orally, once per day (QD) + MK-8742 50 mg tablet, orally, QD for 12 weeks with intensive pharmacokinetic testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5172</intervention_name>
    <arm_group_label>Immediate Treatment</arm_group_label>
    <arm_group_label>Deferred Treatment</arm_group_label>
    <arm_group_label>Immediate Treatment/PK Testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8742</intervention_name>
    <arm_group_label>Immediate Treatment</arm_group_label>
    <arm_group_label>Deferred Treatment</arm_group_label>
    <arm_group_label>Immediate Treatment/PK Testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to MK-5172</intervention_name>
    <arm_group_label>Deferred Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to  MK-8742</intervention_name>
    <arm_group_label>Deferred Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Incluson criteria:

          -  Documented chronic (at least 6 months) HCV GT1 infection (with no evidence of mixed
             genotypes or genotype that cannot be assigned a type)

          -  No evidence of cirrhosis (liver biopsy performed within 24 months of Day 1 of this
             study showing absence of cirrhosis, or Fibroscan performed within 12 months of Day 1
             of this study, or Fibrosure plus Aspartate Aminotransferase to Platelet Ratio Index
             [APRI] obtained during the screening period)

          -  HCV treatment naive or HCV ribonucleic acid (RNA) treatment relapse after a pegylated
             interferon-containing regimen

          -  Chronic kidney disease (defined as glomerular filtration rate [eGFR] &lt;=29)
             non-dialysis dependent or on hemodialysis for at least 3 months, including
             individuals awaiting kidney transplant and those with failed kidney transplants but
             no longer on immunosuppressant therapy)

          -  Female participant of reproductive potential must agree to remain abstinent or use
             (or have their partner use) 2 acceptable methods of contraception from at least 2
             weeks prior to Day 1 through 14 days after the last dose of study drugs, or longer if
             dictated by local regulations

        Exclusion criteria:

          -  Evidence of decompensated liver disease

          -  On peritoneal dialysis for management of kidney disease

          -  Co-infection with hepatitis B virus or human immunodeficiency virus (HIV)

          -  History of malignancy &lt;=5 years prior to signing informed consent

          -  Clinical diagnosis of substance abuse

          -  Pregnant, breast-feeding, expecting to conceive or donate eggs, or donate sperm from
             at least 2 weeks prior to Day 1 and until 14 days after the last study dose, or
             longer if dictated by local regulations

          -  Organ transplant (including hematopoietic stem cell transplant) other than kidney,
             cornea, and hair

          -  Conditions requiring, or likely to require, chronic systemic administration of
             corticosteroids during the course of the trial

          -  Uncontrolled or poorly controlled hypertension

          -  Significant cardiovascular disorder (e.g. myocardial infarction or unstable angina)
             or cardiovascular procedure within 3 months prior to signing informed consent

          -  New or worsening signs or symptoms of congestive heart failure within 3 months of
             signing informed consent

          -  Severe active peripheral vascular disease

          -  Recent (within 3 months prior to signing informed consent) episode or recurrence of
             stroke, transient ischemic attack (TIA) or neurological disorder, including but not
             limited to seizures

          -  Evidence or history of chronic hepatitis not caused by HCV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0608)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0563)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0573)</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0591)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0566)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0603)</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0620)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0567)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0571)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0604)</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0570)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0618)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0562)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0572)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0611)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0561)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0576)</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0609)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0584)</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0615)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0592)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-0139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0613)</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0598)</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0568)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0596)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0594)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0589)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0585)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0581)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0587)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0610)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0579)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0601)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0583)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Jankelowitz</last_name>
      <phone>61 2 8988 8246</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 3L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre / Centre de l'information medicale de Merck Canada</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Blazy</last_name>
      <phone>33 147548990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Sharon</last_name>
      <phone>972 9 9539310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UAB &quot;Merck Sharp &amp; Dohme&quot;</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrius Bacevicius</last_name>
      <phone>370 52780243</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar Sanz Rodriguez</last_name>
      <phone>34 913210600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD</name>
      <address>
        <city>Sollentuna</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tryggve Ljung</last_name>
      <phone>46 (0)70 545 28 66</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Lithuania</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
